Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Advises Medication Error Risk Assessment Early In Development

This article was originally published in The Tan Sheet

Executive Summary

FDA’s draft guidance on safety considerations for product and container design to minimize medication errors calls for assessments in “real world” settings early in the development process. Relying solely on clinical trials is inadequate for a number of factors the agency and sponsors need to know about a new drug product, the draft says.


Related Content

Regulatory News In Brief
In Brief
FDA Gets Strict On Liquid OTC Dosing Devices In Draft Guidance





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts